Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
Authors:
- Razelle KurzrockRKRazelle Kurzrock
- Siqing FuSFSiqing Fu
- Keyvan RezaiKRKeyvan Rezai
- Aby BuchbinderABAby Buchbinder
Open Access
Abstract
BACKGROUND: EZN‐2208 is a water‐soluble, polyethylene glycol drug conjugate of SN38, which is the active moiety of irinotecan. In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN‐2208 in adult patients with advanced solid tumors.METHODS: Patients in sequential cohorts (3 + 3 design) received intravenous EZN‐2208 at doses between 1.25 mg/m2 and 25 mg/m2 once every 21 days.RESULTS: Thirty‐nine patients received EZN‐2208. The median number of prior therapies was 2 (range, 0‐10 prior therapies). Seventeen patients received prior irinotecan. Two maximum tolerated doses (MTDs) were defined: EZN‐2208 with (16.5 mg/m2) and without (10 mg/m2) granulocyte‐colony–stimulating factor (G‐CSF). The dose‐limiting toxicity (DLT) was febrile neutropenia. Two of 19 patients who were heterozygous for a polymorphism in the uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) gene (UGT1A1*28) developed DLTs (dose, 25 mg/m2 with G‐CSF), and 2 patients who were homozygous for UGT1A1*28 were treated without DLTs (dose, 5 mg/m2). PK analysis indicated a mean terminal half‐life of 19.4 ± 3.4 hours. Sixteen patients (41%) achieved stable disease, including 6 of 39 patients (15%) who had stable disease that lasted ≥4 months. One patient with cholangiocarcinoma (no prior irinotecan) achieved a short‐lived 32% tumor regression. Among 6 patients who had stable disease that lasted for ≥4 months, 3 had received prior irinotecan, and 1 had KRAS‐positive colorectal cancer.CONCLUSIONS: EZN‐2208 was well tolerated and produced stable disease that lasted for ≥4 months/unconfirmed partial responses in 7 of 39 heavily pretreated patients (18%) with advanced solid tumors, including those who had failed prior irinotecan therapy. Cancer 2012. © 2012 American Cancer Society.Keywords
This publication has 16 references indexed in Scilit:
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) LinkersBioconjugate Chemistry, 2008
- PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing miceJournal of Controlled Release, 2006
- Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for UGT1A1*28 Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled StudyThe Oncologist, 2006
- Coupling a stochastic approximation version of EM with an MCMC procedureESAIM: Probability and Statistics, 2004
- Irinotecan Pharmacogenetics: Is It Time to Intervene?Journal of Clinical Oncology, 2004
- Modified Fibonacci SearchJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Clinical Pharmacokinetics of IrinotecanClinical Pharmacokinetics, 1997
- Discovery to ClinicaAnnals of the New York Academy of Sciences, 1996